Melbourne Haematology

Prof Hang Quach consults at: East Melbourne

Suite 501, 100 Victoria Parade
East Melbourne, VIC 3002
Tel: 03 9654 8906
Fax 03 9654 8909

View Map of Room's Location

Private Hospital Accreditations
St.Vincent's Private Hospital
Victoria Parade, East Melbourne.
Epworth Richmond. Bridge Road, Richmond.

MBBS(Hons) SpecCertOC FRACP FRCPA MD

• Consultant Haematologist

Professor Hang Quach is a consultant clinical and laboratory Haematologist at St.Vincent’s Hospital. She is also the Director of Haematology Clinical Trials at St.Vincent’s with a portfolio of over 60 clinical studies mainly in multiple myeloma and lymphoma.

Prof Quach's career in haematology is accentuated by her strong involvement in both clinical and laboratory research, that has resulted in many publications in high impact medical journals and attracted many peer-reviewed grants for research. She is passionate about improving the standard of care for patients with blood cancers in Australia, not only through research, but also through active roles on a number of national and international boards and committees, through which she has led a number of published national treatment guidelines and position statements on blood disorders.

Prof Quach is currently the co-chair of the Myeloma Disease Group Committee of the ALLG (Australian Lymphoma and Leukaemia Group). She also serves as a councilor of the Specialist Medical Review Council on multiple myeloma, to the Australian Minister of Veterans' Affairs and leads the development and update of the Australian National Treatment Guideline for Multiple Myeloma as part of her role on the Myeloma Scientific Advisory Group (MSAG) for Myeloma Australia.

Prof Quach's main area of expertise is malignant haematological disorders in particular multiple myeloma, lymphoma, myeloproliferative diseases, myelodysplasia and acute leukaemia. Dr Quach is well known for her dedication and willingness to go to great lengths to achieve optimal outcome for her patients.

Selected Publications

1. Quach H, Benson S, Haysome H, Wilkes A.M, Saher N, Cole-Sinclair M, Prince H M, Mollee P, Ho J, Harrison SJ, Lee C, Auguston B, Daly J. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. Intern Med J. 2018; 48(2):210-220.
2. Quach H, Fernyhough L, Henderson R, Corbett G, Baker B, Browett P, Blacklock H, Forsyth C, Underhill C, Cannell P, Trotman J, Neylon A, Harrison S, Link E, Swern A, Cowan L, Dimopoulos MA, Miles Prince H. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. Br J Haematol 2017; 177(3):441-448.
3. Quach H, White D, Spencer A, Ho PJ, Bhutani D, White M, Inamdar S, Morris C, Ou Y, Gyger M. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. Cancer Chemother Pharmacol 2017; 79(6):1067-1076
4. Hughes TP, Munhoz E, Aurelio Salvino M, Ong TC, Elhaddad A, Shortt J, Quach H, Pavlovsky C, Louw VJ, Shih LY1, Turkina AG, Meillon L, Jin Y, Acharya S, Dalal D, Lipton JH., Novel dose optimization strategies in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with nilotinib: final results from the ENESTxtnd study. Br J Haematol 2017;179(2): 219-228.
5. Talaulikar D, Tam CS, Joshua D, Ho JP, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Horvath N, Lee C, Zannettino A, Brown R, Augustson B, Jaksic W, Gibson J, Kalff A, Johnston A, Trotman J, Kalro A, Grigoriadis G, Ward C, Prince HM., Treatment of Patients with Waldenström Macroglobulinaemia: Position Statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J 2017; 47(1): 35-49
6. Lee OL, Horvath N, Lee C, Joshua D, Ho J, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Talaulikar D, Brown R, Augustson B, Ling S, Jaksic W, Gibson J, Kalff A, Johnston A, Kalro A, Ward C, Prince HM, Zannettino A., Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Int Med J. 2017; 47(8):938-951
7. Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, Straszkowski L, Scott MK, Rothery S, Ruivo N, Foster K, Waibel M, Johnstone RW, Harrison SJ, Westerman DA, Quach H, Gribben J, Robinson MD, Purton LE, Bonnet D, Lo Celso C. T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature. 2016 Oct 27;538(7626):518-522.
8. Cooke RE, Gherardin NA, Harrison SJ, Quach H, Godfrey DI, Prince M, Koldej R, Ritchie DS., Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma. J Transl Med. 2016 14:259
9. Quach H, Joshua D, Ho J, Szer J, Spencer A, Harrison SJ, Mollee P, Roberts AW, Horvath N, Talaulikar D, To B, Zannettino A, Brown R, Catley L, Augustson B, Jaksic W, Gibson J, Prince HM. Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group (MSAG). Intern Med J 2015; 45(1):94-105
10. Quach H, Joshua D, Ho J, Szer J, Spencer A, Harrison SJ, Mollee P, Roberts AW, Horvath N, Talaulikar D, To B, Zannettino A, Brown R, Catley L, Augustson B, Jaksic W, Gibson J, Prince HM., Treatment of Patients with Multiple Myeloma who are NOT Eligible for Stem Cell Transplantation: Position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group (MSAG). Int Med J. 2015 45(3): 335-343.
11. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators,.Ibrutinib a Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 2015; 373(25): 2425-37.
12. Harrison SJ, Quach H, Link E, Feng H, Dean J, Copeman M, Van De Velde H, Schwarer A, Baker B, Spencer A, Catalano J, Campbell P, Augustson B, Romeril K, Prince HM., The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit (original study). Am J Hematol. 2015; 90(5): E86-91
13. Chan AC, Neeson P, Leeansyah E, Tainton K, Quach H, Prince HM, Harrison SJ, Godfrey DI, Ritchie D, Berzins SP., Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy (original study). Clin Exp Immunol. 2014 Jan;175(1):49-58
14. Morschhauser F1, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B., A Phase 2, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®) in Subjects with Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma: the EXPECT Trial. European Journal of Cancer. 2013; 49(13):2689-76
15. Quach H, Davis S., Radiotherapy in orbital lymphoma :optimising the backbone to build upon. Leuk Lymphoma 2013; 54(3):445-6
16. Quach H, Kalff A, Spencer A,.Lenalidomide in multiple myeloma: Current status and future potential. Am J Hematol. 2012 Apr 26. doi: 10.1002/ajh.23234. [Epub ahead of print]
17. Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, Smyth MJ, Neeson P, Ritchie DS., The Immunostimulatory effect of lenalidomide on NK cell function is profoundly inhibited by concurrent dexamethasone therapy [original study]. Blood 2011; 117(5):1605-13
18. Quach H, Prince HM, Spencer A., Treatment Of Multiple Myeloma In The Elderly: Are We Making Progress? [review article]. Expert Rev Hematol 2011; 4 (3):301-305.
19. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM., Mechanism of Action of Immunomodulatory Drugs (IMiDs) in Multiple Myeloma [Review]. Leukemia. 2010;24(1):22-32.
20. Ritchie DS, Quach H, Fielding K, Neeson P., Drug-Mediated and Cellular Immunotherapy in Multiple Myeloma. Immunotherapy Immunotherapy 2010 [Review]; 2(2):243-255.
21. Quach H, Mileshkin L, Seymour JF, Milner A, Ritchie D, Harrison S, Westerman D, Prince HM., Predicting durable remissions following thalidomide therapy for relapsed myeloma [original study]. Leuk Lymphoma 2009; 50 (2): 223-229.
22. Quach H, Horvath N, Cannell P, Mikhael JR, Butcher BE, Prince HM., Safety and efficacy results from an international Expanded Access Program to Bortezomib for patients with relapsed and / or refractory multiple myeloma: a subset analysis of the Australian & New Zealand data of 111 patients. [orignal study] Int Med J 2009; 39(5): 290-5
23. Quach H, Prince HM, Mileshkin L., Treatment Strategies in Elderly Patients with Multiple Myeloma: Current Status [Review]. Drugs Aging 2007;24 (10):829-50.

Society Memberships

• Medical Scientific Advisory Group Australia (MSAG)
• ASH
• Haematology Society of Australia and New Zealand (HSANZ)
• Australasian Leukaemia and Lymphoma Group (ALLG)

Updated: October 2021